Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been given an average rating of “Buy” by the thirteen research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.0833.
A number of research firms have recently commented on TRVI. Raymond James Financial reiterated a “strong-buy” rating and set a $40.00 price target on shares of Trevi Therapeutics in a report on Friday, August 7th. Morgan Stanley restated an “overweight” rating and issued a $23.00 price objective on shares of Trevi Therapeutics in a report on Friday, August 7th. Wall Street Zen cut Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. HC Wainwright increased their target price on Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Finally, Cantor Fitzgerald lifted their target price on Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 7th.
View Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Price Performance
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). As a group, sell-side analysts anticipate that Trevi Therapeutics will post -0.48 EPS for the current year.
Insiders Place Their Bets
In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the transaction, the director owned 6,351 shares in the company, valued at approximately $95,836.59. This represents a 86.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.39% of the company’s stock.
Institutional Trading of Trevi Therapeutics
A number of institutional investors have recently made changes to their positions in TRVI. BlackRock Inc. purchased a new position in shares of Trevi Therapeutics during the second quarter valued at approximately $208,041,000. Artia Global Partners LP purchased a new stake in Trevi Therapeutics in the second quarter worth approximately $41,232,000. First Light Asset Management LLC purchased a new stake in Trevi Therapeutics in the second quarter worth approximately $39,113,000. Bank of America Corp DE bought a new stake in Trevi Therapeutics in the 2nd quarter worth approximately $28,588,000. Finally, Assenagon Asset Management S.A. bought a new stake in Trevi Therapeutics in the 2nd quarter worth approximately $28,447,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.
About Trevi Therapeutics
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.
Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.
Featured Stories
- Five stocks we like better than Trevi Therapeutics
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
